TW202409076A - 抗slc34a2單株抗體及其用途 - Google Patents

抗slc34a2單株抗體及其用途 Download PDF

Info

Publication number
TW202409076A
TW202409076A TW112123436A TW112123436A TW202409076A TW 202409076 A TW202409076 A TW 202409076A TW 112123436 A TW112123436 A TW 112123436A TW 112123436 A TW112123436 A TW 112123436A TW 202409076 A TW202409076 A TW 202409076A
Authority
TW
Taiwan
Prior art keywords
amino acid
acid sequence
seq
higg1
antibody
Prior art date
Application number
TW112123436A
Other languages
English (en)
Chinese (zh)
Inventor
李潤生
黃文韜
李一帆
Original Assignee
中國大陸商上海禮新醫藥研發有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中國大陸商上海禮新醫藥研發有限公司 filed Critical 中國大陸商上海禮新醫藥研發有限公司
Publication of TW202409076A publication Critical patent/TW202409076A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW112123436A 2022-06-22 2023-06-21 抗slc34a2單株抗體及其用途 TW202409076A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022100315 2022-06-22
WOPCT/CN2022/100315 2022-06-22

Publications (1)

Publication Number Publication Date
TW202409076A true TW202409076A (zh) 2024-03-01

Family

ID=89379184

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112123436A TW202409076A (zh) 2022-06-22 2023-06-21 抗slc34a2單株抗體及其用途

Country Status (14)

Country Link
US (2) US12215150B2 (cg-RX-API-DMAC10.html)
EP (1) EP4543926A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025520692A (cg-RX-API-DMAC10.html)
KR (1) KR20250051643A (cg-RX-API-DMAC10.html)
CN (1) CN119948054A (cg-RX-API-DMAC10.html)
AU (1) AU2023289743A1 (cg-RX-API-DMAC10.html)
CA (1) CA3260354A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024004012A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024017740A2 (cg-RX-API-DMAC10.html)
IL (1) IL317849A (cg-RX-API-DMAC10.html)
MX (1) MX2025000053A (cg-RX-API-DMAC10.html)
PE (1) PE20252048A1 (cg-RX-API-DMAC10.html)
TW (1) TW202409076A (cg-RX-API-DMAC10.html)
WO (1) WO2023246879A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024408814A1 (en) * 2023-12-21 2026-07-09 LaNova Medicines Limited Conjugates of anti-slc34a2 antibody and uses thereof
CN120988123B (zh) * 2025-10-21 2026-03-17 苏州近岸蛋白质科技股份有限公司 一种抗人NaPi2b的人源化单克隆抗体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2250201B1 (en) 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Also Published As

Publication number Publication date
US20250154248A1 (en) 2025-05-15
CA3260354A1 (en) 2023-12-28
EP4543926A1 (en) 2025-04-30
CN119948054A (zh) 2025-05-06
JP2025520692A (ja) 2025-07-03
IL317849A (en) 2025-02-01
US12215150B2 (en) 2025-02-04
CO2024017740A2 (es) 2025-05-19
KR20250051643A (ko) 2025-04-17
MX2025000053A (es) 2025-04-02
US20240301052A1 (en) 2024-09-12
WO2023246879A1 (en) 2023-12-28
CL2024004012A1 (es) 2025-05-02
PE20252048A1 (es) 2025-08-21
AU2023289743A1 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
US11873342B2 (en) Anti-CCR8 monoclonal antibodies and uses thereof
US11634490B2 (en) Blocking antibodies against CD47 and methods of use thereof
AU2019218516B2 (en) Antibodies to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and uses thereof
US11028172B1 (en) Anti-TIGIT antibodies and uses thereof
US12570742B2 (en) Anti-SIRPα monoclonal antibodies and uses thereof
US12281162B2 (en) Chimeric antigen receptors targeting GPRC5D
IL281441B2 (en) Anti-cxcl13 antibodies for treating autoimmune diseases and cancer
AU2015276153A1 (en) Anti-axl antibodies
US20250154248A1 (en) Anti-slc34a2 monoclonal antibodies and uses thereof
US20250163164A1 (en) Anti-il-13ra2 monoclonal antibodies and uses thereof
TWI883306B (zh) 抗ｇｐｒｃ５ｄ單株抗體及其用途
HK40126806A (en) Anti-slc34a2 monoclonal antibodies and uses thereof
US20240101716A1 (en) BISPECIFIC ANTIBODIES TARGETING SIRPa AND PD-L1
HK40118089A (en) Anti-il-13ra2 monoclonal antibodies and uses thereof
OA21935A (en) ‘‘Anti-IL-13RA2 Monoclonal Antibodies And Uses Thereof’’
TW202330599A (zh) 抗ｃｃｒ８單株抗體及其用途
HK40080157A (en) Anti-gprc5d monoclonal antibodies and uses thereof
EA048142B1 (ru) Моноклональные антитела к gprc5d и варианты их применения
OA21300A (en) Anti-ccr8 monoclonal antibodies and uses thereof.
EA047699B1 (ru) Конъюгаты антитело-лекарственное средство, нацеленные на клаудин 18.2